RA
AVNS

Royce & Associates’s Avanos Medical AVNS Stock Holding History

Royce & Associates’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.2M Buy
513,703
+453,000
+746% +$6.1M 0.07% 406
2025
Q4 		$682K Buy
60,703
+28,482
+88% +$326K 0.01% 685
2025
Q3 		$372K Buy
+32,221
New +$377K ﹤0.01% 723
2015
Q4 		– Sell
-84,500
Closed -$2.4M – 1122
2015
Q3 		$2.4M Buy
+84,500
New +$2.95M 0.01% 828

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Royce & Associates's AVNS Position: Q1 2026 in Review

Royce & Associates increased its Avanos Medical (AVNS) stake by 746% in Q1 2026, buying an estimated $6.1M and bringing the position to 513,703 shares worth $7.2M. The position accounts for 0.07% of the portfolio, ranked #406.

Royce & Associates first reported a position in AVNS in Q3 2015 and has held it in 4 quarters since. 257 funds tracked by Wall St. Rank hold AVNS as of Q1 2026.

  • Royce & Associates held 513,703 shares of Avanos Medical worth $7.2M as of Q1 2026.
  • Royce & Associates bought 453,000 Avanos Medical shares in Q1 2026, an estimated $6.1M.
  • Avanos Medical made up 0.07% of Royce & Associates's portfolio in Q1 2026, its #406 holding.
  • Royce & Associates first reported a position in Avanos Medical in Q3 2015 and has held it in 4 quarters since.
  • 257 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.